{
    "id": 55,
    "premise": "none",
    "hypothesis": "Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR",
    "label": "entailment",
    "explanation": "Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR",
        "history explanation": [
            "0 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "1 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "2 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "3 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "4 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "5 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "6 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "7 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "8 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "9 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "10 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNA :: \"event \u21d2 bool\"\\n  Damage :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient e BRCA2 \u2227 SitesOfDNADamage z \u2227 Links e \u2227 Agent e y \u2227 Patient e BRCA1 \u2227 Patient e BRCA2 \u2227 HRRepair e \u2227 DNA e \u2227 Damage e\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Patient e y \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203x y e. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know about the loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  \\n  (* We have the explanation that PALB2 encodes a binding partner that links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\n  (* This implies that BRCA2 is involved in HR repair and DNA damage. *)\\n  (* Since BRCA2 promotes the joining of undamaged homologous repair molecules, it is related to joining undamaged repair molecules. *)\\n  (* Therefore, we can infer that BRCA2 is related to joining undamaged repair molecules. *)\\n  then have \"Joining e\" and \"UndamagedHomologousRepairMolecules e\" <ATP>\\n  \\n  (* We need to show that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  (* We can combine the information we have to form the required conclusion. *)\\n  then have \"Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules e\" <ATP>\\n  then have \"\u2203x y e. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules e\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNA :: \"event \u21d2 bool\"\\n  Damage :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient e BRCA2 \u2227 SitesOfDNADamage z \u2227 Links e \u2227 Agent e y \u2227 Patient e BRCA1 \u2227 Patient e BRCA2 \u2227 HRRepair e \u2227 DNA e \u2227 Damage e\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Patient e y \u2227 Via e RAD51Homolog1 z \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know about the loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  \\n  (* We have the logical relation Implies(A, C), Implies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans) *)\\n  (* We can infer that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  from explanation_1 and explanation_3 have \"BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\" <ATP>\\n  \\n  (* Now, we can combine the known information and the inferred information to prove the hypothesis. *)\\n  then have \"Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient with a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  DNADamage :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient e BRCA2 \u2227 To e SitesOfDNADamage \u2227 Links e \u2227 Agent e y \u2227 Patient e BRCA1 \u2227 Patient e BRCA2 \u2227 In e HRRepair \u2227 In e DNADamage\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Patient e y \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know that there is a patient with a pathogenic mutation in PALB2. *)\\n  from asm obtain z where \"Patient z \u2227 PathogenicMutation x \u2227 In x PALB2\" <ATP>\\n  \\n  (* We have the information that PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\n  have \"\u2203y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient e BRCA2 \u2227 To e SitesOfDNADamage \u2227 Links e \u2227 Agent e y \u2227 Patient e BRCA1 \u2227 Patient e BRCA2 \u2227 In e HRRepair \u2227 In e DNADamage\"\\n    <ATP>\\n  \\n  (* We also know that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  have \"\u2203y z e. BRCA2 y \u2227 Joining z \u2227 UndamagedHomologousRepairMolecules z \u2227 Promotes e \u2227 Agent e y \u2227 Patient e z \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n    <ATP>\\n  \\n  (* Combining the above information, we can infer that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.910281896591187, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_55_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"event \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNA :: \"event \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  HomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In x y \u2227 PALB2 y\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 BRCA2 z \u2227 SitesOfDNADamage z \u2227 Links e \u2227 BRCA1 e \u2227 BRCA2 z \u2227 HRRepair e \u2227 DNA e\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z e. BRCA2 x \u2227 Promotes e \u2227 Joining y \u2227 Undamaged y \u2227 HomologousRepairMolecules y \u2227 RAD51Homolog1 z \u2227 Humans z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 RepairMolecules e \u2227 Undamaged e \u2227 HRR e\"\\nproof -\\n  (* From the premise, we know about the loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  \\n  (* We have the logical proposition B, which states that PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\n  (* This implies that if PALB2 is present, then BRCA2 is linked to HR repair and DNA damage. *)\\n  (* Since BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, we can infer that the loss of PALB2 prevents this action of BRCA2. *)\\n  then have \"Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 RepairMolecules e \u2227 Undamaged e \u2227 HRR e\" <ATP>\\n  \\n  (* Therefore, we can conclude that there exists e, x, and y such that the given conditions hold. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient y \u2227 BRCA2 y \u2227 To e \u2227 Links e \u2227 In e Humans\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Patient y \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know about the loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans) *)\\n  (* We can infer that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  then have \"BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\" <ATP>\\n  (* The hypothesis states that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  (* There is a logical relation Implies(Not(C), Not(A)), Implies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2)) *)\\n  (* Therefore, we can conclude that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient with a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  DNADamage :: \"entity \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient e BRCA2 \u2227 SitesOfDNADamage z \u2227 Links e \u2227 Agent e y \u2227 Patient e BRCA1 \u2227 Patient e BRCA2 \u2227 In e HRRepair \u2227 In e DNADamage\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Patient e y \u2227 Via e \u2227 Patient e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know about the loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  \\n  (* We have the logical relation Implies(A, C), Implies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans) *)\\n  (* Since we have PALB2 x, we can infer BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  from explanation_1 and explanation_2 have \"BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\" <ATP>\\n  \\n  (* We aim to prove the hypothesis which includes Loss e, PALB2 x, BRCA2 y, Action e, Prevents e, Agent e x, Patient e y, Joining e, UndamagedRepairMolecules e, and In e HRR. *)\\n  (* We can combine the known information and the derived implication to reach the conclusion. *)\\n  then have \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules e \u2227 In e HRRepair\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient with a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNARepair :: \"event \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient e BRCA2 \u2227 SitesOfDNADamage z \u2227 Links e \u2227 Agent e y \u2227 Patient e BRCA1 \u2227 Patient e BRCA2 \u2227 HRRepair e \u2227 DNARepair e\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Patient e y \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know that there is a patient with a pathogenic mutation in PALB2. *)\\n  from asm obtain x y where \"Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\" by auto\\n  (* We have the information from explanatory sentence 2 that PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\n  (* This implies that BRCA2 is linked to PALB2. *)\\n  have \"BRCA2 x\" <ATP>\\n  (* We also know from explanatory sentence 3 that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  (* This implies that BRCA2 is involved in joining undamaged repair molecules. *)\\n  have \"Joining e \u2227 UndamagedHomologousRepairMolecules e\" <ATP>\\n  (* Therefore, we can conclude that there exists an event, entities x and y such that Loss e, PALB2 x, BRCA2 y, Action e, Prevents e, Agent e x, Patient e y, Joining e, UndamagedHomologousRepairMolecules e, and In e HRR hold. *)\\n  then show ?thesis by auto\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Theme :: \"event \u21d2 entity \u21d2 bool\"\\n  At :: \"event \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Theme e BRCA2 \u2227 At e SitesOfDNADamage \u2227 Links e \u2227 In e HRRepair \u2227 In e DNADamage\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Theme e y \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know about the loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  (* We have the logical relation Implies(A, C), Implies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans). *)\\n  (* Since we have PALB2 x and BRCA2 y, we can infer BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  then have \"BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51Homolog1 in Humans\" <ATP>\\n  (* The hypothesis states that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  (* We can combine the known information and the derived implication to conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient with a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  HRRepair :: \"entity\"\\n  DNADamage :: \"entity\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity\"\\n  Humans :: \"entity\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 Agent e y \u2227 Patient y \u2227 SitesOfDNADamage z \u2227 Links e \u2227 In z HRRepair \u2227 In z DNADamage\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules y \u2227 Promotes e \u2227 Agent e x \u2227 Via e RAD51Homolog1 \u2227 In e Humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient y \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules e \u2227 In e HRRepair\"\\nproof -\\n  (* From the premise, we know that there is a patient with a pathogenic mutation in PALB2. *)\\n  obtain p m where patient_pathogenic: \"Patient p \u2227 PathogenicMutation m \u2227 In m PALB2\" <ATP>\\n  (* From the known information and Explanation 2, we can infer that PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\n  obtain b l s h where palb2_binding: \"PALB2 x \u2227 BindingPartner b \u2227 Localises l \u2227 Agent l b \u2227 Patient b \u2227 SitesOfDNADamage s \u2227 Links l \u2227 In s HRRepair \u2227 In s DNADamage\" <ATP>\\n  (* From the known information and Explanation 3, we can deduce that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  obtain j u r v where brca2_promotes: \"BRCA2 y \u2227 Joining j \u2227 UndamagedHomologousRepairMolecules u \u2227 Promotes j \u2227 Agent j y \u2227 Via j RAD51Homolog1 \u2227 In j Humans\" <ATP>\\n  (* Since PALB2 encodes a binding partner that localises BRCA2 and BRCA2 promotes the joining of repair molecules, we can conclude that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  have \"Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient y \u2227 Joining e \u2227 UndamagedHomologousRepairMolecules e \u2227 In e HRRepair\" <ATP>\\n  then show ?thesis by blast\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient with a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  PathogenicMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  SitesOfDNADamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNARepair :: \"event \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Joining :: \"entity \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 BRCA2 z \u2227 SitesOfDNADamage z \u2227 Links e \u2227 BRCA1 e \u2227 BRCA2 z \u2227 HRRepair e \u2227 DNARepair e\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Promotes e \u2227 Joining y \u2227 UndamagedHomologousRepairMolecules y \u2227 RAD51Homolog1 z \u2227 In z humans\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 PathogenicMutation y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e. LossOfPALB2(e) \u2227 Prevents(e) \u2227 ActionOfBRCA2(e) \u2227 Joining(e) \u2227 UndamagedRepairMolecules(e) \u2227 In(e, HRR)\"\\nproof -\\n  (* From the premise, we know that there is a patient with a pathogenic mutation in PALB2. *)\\n  from asm obtain x y where \"Patient x \u2227 PathogenicMutation y \u2227 In y PALB2\" by (rule explanation_1)\\n  (* We have the information about PALB2 from explanatory sentence 2. *)\\n  obtain z e where \"PALB2 x \u2227 BindingPartner z \u2227 Localises e \u2227 BRCA2 z \u2227 SitesOfDNADamage z \u2227 Links e \u2227 BRCA1 e \u2227 BRCA2 z \u2227 HRRepair e \u2227 DNARepair e\" <ATP>\\n  (* We also have the information about BRCA2 from explanatory sentence 3. *)\\n  obtain w v u t where \"BRCA2 w \u2227 Promotes t \u2227 Joining v \u2227 UndamagedHomologousRepairMolecules v \u2227 RAD51Homolog1 u \u2227 In u humans\" <ATP>\\n  (* Since PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, and BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, we can infer the hypothesis. *)\\n  then have \"LossOfPALB2 e \u2227 Prevents e \u2227 ActionOfBRCA2 e \u2227 Joining e \u2227 UndamagedRepairMolecules e \u2227 In e HRR\" sorry\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Sites :: \"event \u21d2 bool\"\\n  DNA :: \"event \u21d2 bool\"\\n  Damage :: \"event \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"event \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  RepairMolecules :: \"event \u21d2 bool\"\\n  Undamaged :: \"event \u21d2 bool\"\\n  Homologous :: \"event \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 In x y PALB2\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PALB2 x \u2227 BindingPartner y \u2227 Localises e \u2227 BRCA2 z \u2227 Sites e \u2227 DNA e \u2227 Damage e \u2227 Links e \u2227 BRCA1 e \u2227 HRRepair e \u2227 DNA e \u2227 Damage e\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. BRCA2 x \u2227 Promotes e \u2227 Joining e \u2227 RepairMolecules e \u2227 Undamaged e \u2227 Homologous e \u2227 RAD51Homolog1 y \u2227 Humans z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Loss e \u2227 PALB2 x \u2227 BRCA2 y\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n shows \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 RepairMolecules e \u2227 Undamaged e \u2227 In e HRR\"\\nproof -\\n  (* From the premise, we know about Loss, PALB2, and BRCA2. *)\\n  from asm have \"Loss e\" and \"PALB2 x\" and \"BRCA2 y\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans) *)\\n  (* Both A and C are from explanatory sentences 1 and 3. *)\\n  (* We already have BRCA2 y, so we can infer BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  then have \"BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\" <ATP>\\n  (* We need to show the existence of e, x, and y satisfying the required conditions. *)\\n  (* We can combine the known information and the derived implication to reach the conclusion. *)\\n  then have \"\u2203e x y. Loss e \u2227 PALB2 x \u2227 BRCA2 y \u2227 Action e \u2227 Prevents e \u2227 Agent e x \u2227 Patient e y \u2227 Joining e \u2227 RepairMolecules e \u2227 Undamaged e \u2227 In e HRR\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patient with a pathogenic mutation in PALB2\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patient with a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Patient with a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(Patient with a pathogenic mutation in PALB2))\\n--------\\n'}"
        ]
    }
}